Chromium Picolinate Formula Lowers CVD Risk In Type II Diabetics

Chromium Picolinate Formula Lowers CVD Risk In Type II Diabetics

WASHINGTONChromium picolinate formulated with biotin lowers cardiovascular disease (CVD) risk factors in Type II diabetics, according to research presented at the American Heart Associations sixth Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, held here.

In the randomized double blind, placebo-controlled, multi-center study, 368 Type II diabetes patients received a placebo or chromium picolinate and biotin (as Diachrome®, supplied by Nutrition 21) for 12 weeks. Non-high-density lipoprotein (HDL) cholesterol was significantly lowered (by 14 mg/dL) in Type II diabetes patients already receiving statin therapy or other cholesterol-lowering prophylaxes, compared to the placebo group. In addition, test subjects who took Diachrome had significantly lower triglyceride levels (225 mg/dL) compared to individuals in the placebo group (278 mg/dL).

These results are impressive since glucose lowering medications do not commonly reduce bad cholesterol levels, and frequently raise them as a side effect, said Cesar Albarracin, M.D., lead researcher. The findings from this study suggest that Diachrome can serve as a safe and effective adjunct therapy to diet and prescription medications in lowering both blood glucose and cholesterol levels.